AAAAAA
Results:
1-24
|
Results: 24
Authors:
Buchner, T
Hiddemann, W
Schoch, C
Haferlach, T
Sauerland, MC
Heinecke, A
Citation: T. Buchner et al., Acute myeloid leukaemia (AML): treatment of the older patient, BEST P R C, 14(1), 2001, pp. 139-151
Authors:
Pabst, T
Mueller, BU
Harakawa, N
Schoch, C
Haferlach, T
Behre, G
Hiddemann, W
Zhang, DE
Tenen, DG
Citation: T. Pabst et al., AML1-ETO downregulates the granulocytic differentiation factor C/EBP alphain t(8;21) myeloid leukemia, NAT MED, 7(4), 2001, pp. 444-451
Authors:
Nickenig, C
Lang, NK
Schoch, C
Hiddemann, W
Haferlach, T
Citation: C. Nickenig et al., New insights into the biology of multiple myeloma using a combination of May-Grunwald-Giemsa staining and fluorescence in situ hybridization techniques at the single cell level, ANN HEMATOL, 80(11), 2001, pp. 662-668
Authors:
Wuchter, C
Ratei, R
Spahn, G
Schoch, C
Harbott, J
Schnittger, S
Haferlach, T
Creutzig, U
Sperling, C
Karawajew, L
Ludwig, WD
Citation: C. Wuchter et al., Impact of CD133 (AC133) and CD90 expression analysis for acute leukemia immunophenotyping, HAEMATOLOG, 86(2), 2001, pp. 154-161
Authors:
Buchner, T
Hiddemann, W
Berdel, W
Wormann, B
Loffler, H
Schoch, C
Haferlach, T
Ludwig, WD
Maschmeyer, G
Staib, P
Andreesen, R
Balleisen, L
Haase, D
Eimermacher, H
Aul, C
Rasche, H
Uhlig, J
Gruneisen, A
Reis, HE
Hartlapp, J
Hirschmann, WD
Weh, HJ
Pielken, HJ
Gassmann, W
Sauerland, MC
Heinecke, A
Citation: T. Buchner et al., Remission induction therapy: the more intensive the better?, CANC CHEMOT, 48, 2001, pp. S41-S44
Authors:
Schoch, C
Bursch, S
Kern, W
Schnittger, S
Hiddemann, W
Haferlach, T
Citation: C. Schoch et al., Gain of an isochromosome 5p: a new recurrent chromosome abnormality in acute monoblastic leukemia, CANC GENET, 127(1), 2001, pp. 85-88
Authors:
Haferlach, T
Citation: T. Haferlach, Quantitative reverse transcriptase-polymerase chain reaction in AML with t(8;21)(q22;q22), LEUK RES, 25(1), 2001, pp. 55-56
Authors:
Braess, J
Jahns-Streubel, G
Schoch, C
Haase, D
Haferlach, T
Fiegl, M
Voss, S
Kern, W
Schleyer, E
Hiddemann, W
Citation: J. Braess et al., Proliferative activity of leukaemic blasts and cytosine arabinoside pharmacodynamics are associated with cytogenetically defined prognostic subgroupsin acute myeloid leukaemia, BR J HAEM, 113(4), 2001, pp. 975-982
Authors:
Schoch, C
Haferlach, T
Haase, D
Fonatsch, C
Loffler, H
Schlegelberger, B
Staib, P
Sauerland, MC
Heinecke, A
Buchner, T
Hiddemann, W
Citation: C. Schoch et al., Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients, BR J HAEM, 112(1), 2001, pp. 118-126
Authors:
Schoch, C
Kern, W
Krawitz, P
Dugas, M
Schnittger, S
Haferlach, T
Hiddemann, W
Citation: C. Schoch et al., Dependence of age-specific incidence of acute myeloid leukemia on karyotype, BLOOD, 98(12), 2001, pp. 3500-3500
Authors:
Schnittger, S
Kinkelin, U
Schoch, C
Haase, D
Haferlach, T
Buchner, T
Wormann, B
Hiddemann, W
Griesinger, F
Citation: S. Schnittger et al., MLL-duplications are rare and associated with poor prognosis in acute myeloid leukemia, HEMAT BLOOD, 40, 2001, pp. 27-33
Authors:
Schnittger, S
Schoch, C
Griesinger, F
Buchner, T
Loffler, H
Haferlach, T
Hiddemann, W
Citation: S. Schnittger et al., RT-PCR in diagnostics and monitoring of acute myeloid, HEMAT BLOOD, 40, 2001, pp. 44-48
Authors:
Schoch, C
Klaus, M
Bursch, S
Buchner, T
Loffler, H
Haferlach, T
Hiddemann, W
Citation: C. Schoch et al., Although patients with AML and complex aberrant karyotype can be subdivided into different subtypes by cytogenetics, prognosis is equally poor, HEMAT BLOOD, 40, 2001, pp. 172-175
Authors:
Kern, W
Schoch, C
Haferlach, T
Braess, J
Unterhalt, M
Wormann, B
Buchner, T
Hiddemann, W
Citation: W. Kern et al., Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy: Significance of cytogenetic abnormalities, HEMAT BLOOD, 40, 2001, pp. 330-338
Authors:
Buchner, T
Hiddemann, W
Schoch, C
Haferlach, T
Eimermacher, H
Staib, P
Balleisen, L
Reis, HE
Pielken, HJ
Reichle, A
Schmoll, HJ
Griesinger, F
Gruneisen, A
Sauerland, MC
Heinecke, A
Citation: T. Buchner et al., Treatment of older patients with acute myeloid leukemia (AML), HEMAT BLOOD, 40, 2001, pp. 611-620
Authors:
Buchner, T
Hiddemann, W
Wormann, B
Loffler, H
Ludwig, WD
Schoch, C
Haferlach, T
Maschmeyer, G
Staib, P
Aul, C
Heyll, A
Gruneisen, A
Rasche, H
Eimermacher, H
Balleisen, L
Pielken, HJ
Reis, HE
Griesinger, F
Reichle, A
Sauerland, MC
Heinecke, A
Citation: T. Buchner et al., Acute myeloid leukemia in adults: Is postconsolidation maintenance therapynecessary?, INT J HEMAT, 72(3), 2000, pp. 285-289
Authors:
Lengfelder, E
Reichert, A
Schoch, C
Haase, D
Haferlach, T
Loffler, H
Staib, P
Heyll, A
Seifarth, W
Saussele, S
Fonatsch, C
Gassmann, W
Ludwig, WD
Hochhaus, A
Beelen, D
Aul, C
Sauerland, MC
Heinecke, A
Hehlmann, R
Wormann, B
Hiddemann, W
Buchner, T
Citation: E. Lengfelder et al., Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia, LEUKEMIA, 14(8), 2000, pp. 1362-1370
Authors:
Wuchter, C
Harbott, J
Schoch, C
Schnittger, S
Borkhardt, A
Karawajew, L
Ratei, R
Ruppert, V
Haferlach, T
Creutzig, U
Dorken, B
Ludwig, WD
Citation: C. Wuchter et al., Detection of acute leukemia cells with mixed lineage leukemia (MLL) gene rearrangements by flow cytometry using monoclonal antibody 7.1, LEUKEMIA, 14(7), 2000, pp. 1232-1238
Authors:
Schnittger, S
Kinkelin, U
Schoch, C
Heinecke, A
Haase, D
Haferlach, T
Buchner, T
Wormann, B
Hiddemann, W
Griesinger, F
Citation: S. Schnittger et al., Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML, LEUKEMIA, 14(5), 2000, pp. 796-804
Authors:
Kern, W
Schoch, C
Haferlach, T
Braess, J
Unterhalt, M
Wormann, B
Buchner, T
Hiddemann, W
Citation: W. Kern et al., Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy: relevance of cytogenetic abnormalities, LEUKEMIA, 14(2), 2000, pp. 226-231
Authors:
Wuchter, C
Karawajew, L
Ruppert, V
Schrappe, M
Buchner, T
Schoch, C
Haferlach, T
Harbott, JN
Ratei, R
Dorken, B
Ludwig, WD
Citation: C. Wuchter et al., Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia, HAEMATOLOG, 85(7), 2000, pp. 711-721
Authors:
Braess, J
Voss, S
Jahns-Streubel, G
Schoch, C
Haferlach, T
Kern, W
Keye, S
Schleyer, E
Hiddemann, W
Citation: J. Braess et al., The pharmacodynamic basis for the increased antileukaemic efficacy of cytosine arabinoside-based treatment regimens in acute myeloid leukaemia with ahigh proliferative activity, BR J HAEM, 110(1), 2000, pp. 170-179
Authors:
Gahn, B
Wendenburg, B
Troff, C
Neef, J
Grove, D
Haferlach, T
Hiddemann, W
Wormann, B
Citation: B. Gahn et al., Analysis of progenitor cell involvement in B-CLL by simultaneous immunophenotypic and genotypic analysis at the single cell level, BR J HAEM, 105(4), 1999, pp. 955-959
Authors:
Buchner, T
Wormann, B
Loffler, H
Gassmann, W
Haferlach, T
Fonatsch, C
Haase, D
Schoch, C
Hossfeld, D
Lengfelder, E
Aul, C
Heyll, A
Maschmeyer, G
Ludwig, WD
Sauerland, MC
Heinecke, A
Citation: T. Buchner et al., Double induction strategy for acute myeloid leukemia: The effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: A randomized trial by the German AML Cooperative Group, BLOOD, 93(12), 1999, pp. 4116-4124
Risultati:
1-24
|